Unicycive Therapeutics, Inc. (UNCY): Nasdaq/NYSE listing notice — Unicycive receives Nasdaq delisting notice for bid price non-compliance; equity below $5M

Unicycive Therapeutics, Inc.

On Feb 1, 2023, Nasdaq notified Unicycive (UNCY) that it failed to regain minimum bid price compliance by Jan 30 deadline.
Company not eligible for second 180-day grace period because stockholders' equity of $4.626M was below $5M initial listing requirement.
Unicycive requested a hearing before the Nasdaq Hearings Panel, scheduled for March 23, 2023, to stay delisting.
If Panel grants extension, company may have until August 8, 2023 to cure bid-price deficiency.
Common stock continues trading on Nasdaq under symbol UNCY pending hearing outcome.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Unicycive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Unicycive Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-008965

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.